CN Bio
CN Bio is a close-knit team of passionate scientists, engineers and creative thinkers, all working together towards a shared goal – a future where drugs are discovered more quickly, brought to patients more cost-effectively and with less animal experimentation. Day to day, their cohesive team design, manufacture, promote and support organ-on-a-chip solutions that enable their customers to do something incredible – recreate three-dimensional human organs and tissues in the laboratory to improve understanding of human physiology, disease and the effectiveness of new drugs.
Latest CN Bio Content
CN Bio Launches PhysioMimix Bioavailability Assay Kit: Human 18
A Reflection on Global Fatty Liver Day 2024: How Organ-on-a-Chip Addresses R&D Challenges
CN Bio and Altis Biosystems Partner To Develop Next-Generation Human Gut/Liver In Vitro Model
CN Bio PhysioMimix Organ-on-a-Chip Data Supports Inipharm’s INI-822 for Metabolic Liver Disease Treatment
CN Bio and LifeNet Health LifeSciences Partner To Supply Validated Primary Human Cells for Microphysiological Systems
CN Bio Extends Microphysiological System Portfolio
The FDA Expands Collaboration With CN Bio To Evaluate Multi-Organ Microphysiological System
CN Bio Appoints Dr Paul Brooks as Chief Executive Officer
The Human Touch: How Liver-on-a-Chip Addresses the Unmet Needs of Liver Disease Research
• Liver disease progresses from a dysregulation of metabolism
• Lipid metabolism differs between mice and men and the impact this has on drug development
• Primary human NASH models can evaluate drugs that target metabolism
• NASH models allow the quantitation of lipid droplets, metabolism and fibrosis